|
gptkbp:instanceOf
|
gptkb:drug
gptkb:immune_response_modifier
|
|
gptkbp:approvedBy
|
1997
|
|
gptkbp:ATCCode
|
D06BB10
|
|
gptkbp:brand
|
gptkb:Zyclara
Aldara
|
|
gptkbp:CASNumber
|
99011-02-6
|
|
gptkbp:chemicalFormula
|
C14H16N4
|
|
gptkbp:contraindication
|
hypersensitivity to imiquimod
|
|
gptkbp:developedBy
|
gptkb:3M_Pharmaceuticals
|
|
gptkbp:discoveredBy
|
gptkb:3M
|
|
gptkbp:eliminationHalfLife
|
2 hours
|
|
gptkbp:excretion
|
urine
feces
|
|
gptkbp:genericAvailable
|
true
|
|
gptkbp:isApprovedDrug
|
true
|
|
gptkbp:KEGGID
|
D04568
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
TLR7 agonist
|
|
gptkbp:MeSH_ID
|
D020253
|
|
gptkbp:metabolism
|
hepatic
|
|
gptkbp:molecularWeight
|
240.3 g/mol
|
|
gptkbp:pregnancyCategory
|
C (US)
B3 (Australia)
|
|
gptkbp:PubChem_CID
|
CHEMBL685
57469
DB00724
|
|
gptkbp:routeOfAdministration
|
topical
|
|
gptkbp:sideEffect
|
edema
erosion
itching
burning
ulceration
erythema
local skin reactions
|
|
gptkbp:UNII
|
F6F0HK1URN
|
|
gptkbp:usedFor
|
gptkb:actinic_keratosis
external genital warts
superficial basal cell carcinoma
|
|
gptkbp:bfsParent
|
gptkb:Zyclara
|
|
gptkbp:bfsLayer
|
7
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
imiquimod
|